Activators of TNAP function may be useful for the treatment of milder forms of hypophosphatasia, as the therapeutic use of TNAP activators might sufficiently enhance residual TNAP activity to help resolve or prevent the rickets/osteomalacia characteristic of the disease and may also be useful as a means of increasing bone mineral density in patients with osteoporosis. Here, ALPL is linked to hypophosphatasia.